Chemistry and Art of Developing Lipid Nanoparticles for Biologics Delivery: Focus on Development and Scale-Up

• Published in: Pharmaceutics 2024-01, Vol.16 (1), p.131
• Main Authors: John, Rijo, Monpara, Jasmin, Swaminathan, Shankar, Kalhapure, Rahul
• Format: Article
• Language: English
• Subjects: Biodegradation; Biological products; biologics; Biopharmaceutics; Bupivacaine; cationic lipid; Complications and side effects; Drug delivery systems; lipid nanoparticles; Lipids; liposome; Nanoparticles; nucleic acids; Product development; Proteins; Review; RNA; Verteporfin
• ISSN: 1999-4923; 1999-4923
• DOI: 10.3390/pharmaceutics16010131

Lipid nanoparticles (LNPs) have gained prominence as primary carriers for delivering a diverse array of therapeutic agents. Biological products have achieved a solid presence in clinical settings, and the anticipation of creating novel variants is increasing. These products predominantly encompass therapeutic proteins, nucleic acids and messenger RNA. The advancement of efficient LNP-based delivery systems for biologics that can overcome their limitations remains a highly favorable formulation strategy. Moreover, given their small size, biocompatibility, and biodegradation, LNPs can proficiently transport therapeutic moiety into the cells without significant toxicity and adverse reactions. This is especially crucial for the existing and upcoming biopharmaceuticals since large molecules as a group present several challenges that can be overcome by LNPs. This review describes the LNP technology for the delivery of biologics and summarizes the developments in the chemistry, manufacturing, and characterization of lipids used in the development of LNPs for biologics. Finally, we present a perspective on the potential opportunities and the current challenges pertaining to LNP technology.